Skip to main content

Context Therapeutics, Inc. (CNTX)

Context Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $12.00 - $14.00
Current IPO price range
Chart not available yet
Market Cap90.13M
Revenue (ttm)n/a
Net Income (ttm)4.93M
Shares Out6.93M
EPS (ttm)0.71
PE Ratio18.30
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About CNTX

Context Therapeutics® is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. Our development team is advancing a pipeline of innovative therapies with a primary focus on treating female cancers, which include, but are not limited to, breast, ovarian and endometrial cancer. Our first program and lead product candidate, onapristone extended release (“ONA-XR”), builds upon a foundation of successful drug development by our management team and advisors in the field of female hormone-dependen...

IndustryPharmaceutical Preparations
IPO DatePending
CEOMartin Lehr
Employees2
Stock ExchangeNASDAQ
Ticker SymbolCNTX
Full Company Profile

Financial Performance

Financial Statements

News

Context Therapeutics IPO Registration Document (S-1)

Context Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC